540 related articles for article (PubMed ID: 32194854)
1. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
2. Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel.
Jin H; Wan C; Zou Z; Zhao G; Zhang L; Geng Y; Chen T; Huang A; Jiang F; Feng JP; Lovell JF; Chen J; Wu G; Yang K
ACS Nano; 2018 Apr; 12(4):3295-3310. PubMed ID: 29558107
[TBL] [Abstract][Full Text] [Related]
3. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
4. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
5. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
6. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
7. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Design of an Injectable Polypeptide Hydrogel Depot Containing the Immune Checkpoint Blocker Anti-PD-L1 and Doxorubicin to Enhance Antitumor Combination Therapy.
Shi Y; Li D; He C; Chen X
Macromol Biosci; 2021 Jun; 21(6):e2100049. PubMed ID: 33871152
[TBL] [Abstract][Full Text] [Related]
10. The inhibitor of calcium/calmodulin-dependent protein kinase II KN93 attenuates bone cancer pain via inhibition of KIF17/NR2B trafficking in mice.
Liu Y; Liang Y; Hou B; Liu M; Yang X; Liu C; Zhang J; Zhang W; Ma Z; Gu X
Pharmacol Biochem Behav; 2014 Sep; 124():19-26. PubMed ID: 24836181
[TBL] [Abstract][Full Text] [Related]
11. Acute inhibition of Ca2+/calmodulin-dependent protein kinase II reverses experimental neuropathic pain in mice.
Chen Y; Luo F; Yang C; Kirkmire CM; Wang ZJ
J Pharmacol Exp Ther; 2009 Aug; 330(2):650-9. PubMed ID: 19478130
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
13. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.
Meng J; Yang X; Huang J; Tuo Z; Hu Y; Liao Z; Tian Y; Deng S; Deng Y; Zhou Z; Lovell JF; Jin H; Liu Y; Yang K
Adv Sci (Weinh); 2023 Jul; 10(20):e2300517. PubMed ID: 37132587
[TBL] [Abstract][Full Text] [Related]
15. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
16. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
17. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
18. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
19. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
20. Supramolecular Peptide Amphiphile Nanospheres Reprogram Tumor-associated Macrophage to Reshape the Immune Microenvironment for Enhanced Breast Cancer Immunotherapy.
Xiao Q; Huang J; Wang X; Chen Z; Zhang W; Liu F; Li J; Yang Z; Zhan J; Cai Y
Small; 2024 May; 20(21):e2307390. PubMed ID: 38100300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
